Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$190.61B | 16.1x | -0.82 | HK$63.20 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.1% Upside | Upgrade to Pro+ | |
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$190.60B | -60.7x | -1.25 | HK$137.10 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.3% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$96.87B | 27.3x | 16.78 | HK$23.55 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.6% Upside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$72.97B | -133.5x | 1.1 | HK$83.50 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.4% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$68.97B | -223x | -4.32 | HK$321.20 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2% Upside | Upgrade to Pro+ | |
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$44.15B | 21.7x | 0.77 | HK$13.40 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$39.25B | 108.5x | -1.33 | HK$25.35 | -5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.4% Upside | Upgrade to Pro+ | |
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$26.58B | -15.1x | -1.5 | HK$40.30 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.5% Downside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$22.12B | -43.6x | -0.01 | HK$10.20 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Innocare | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$20.40B | -33.8x | -1.44 | HK$9.92 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.2% Upside | Upgrade to Pro+ | |
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$15.17B | -30.1x | -0.63 | HK$44.85 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.3% Upside | Upgrade to Pro+ | |
Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.59B | 158.7x | -1.85 | HK$9.70 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.4% Downside | Upgrade to Pro+ | |
Keymed Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$11.12B | -22.9x | 0.49 | HK$40.85 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.4% Upside | Upgrade to Pro+ | |
CARsgen Therapeutics Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$10.61B | -9.9x | 1.47 | HK$19.32 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -47.7% Downside | Upgrade to Pro+ | |
TYK Medicines | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$9.42B | -25.1x | -2.05 | HK$23.65 | -6.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alphamab | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$6.38B | 43.3x | 0.22 | HK$6.70 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -27.2% Downside | Upgrade to Pro+ | |
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$5.15B | 166.6x | 1.52 | HK$8.19 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.7% Upside | Upgrade to Pro+ | |
Biocytogen Pharmaceuticals Beijing | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.74B | 154.7x | 1.24 | HK$12.02 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.8% Upside | Upgrade to Pro+ | |
Jiangsu Recbio Technology | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.43B | -6.3x | -3.38 | HK$9.18 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.4% Upside | Upgrade to Pro+ | |
CStone | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.84B | -34.5x | -0.5 | HK$2.86 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jacobio Pharmaceuticals Group | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.47B | -18.2x | -0.33 | HK$4.29 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -53% Downside | Upgrade to Pro+ | |
ImmuneOnco Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.85B | -7x | -0.38 | HK$6.98 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qyuns Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.45B | -6.9x | -0.18 | HK$11.06 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Frontage Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.33B | 370.5x | -4.05 | HK$1.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -13.1% Downside | Upgrade to Pro+ | |
Antengene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.20B | -5.5x | -0.13 | HK$3.42 | 5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -41.9% Downside | Upgrade to Pro+ | |
Hua Medicine | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.06B | -7.7x | 0.43 | HK$2.09 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.80B | -9.2x | -0.21 | HK$3.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.79B | -13.9x | -0.34 | HK$0.44 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HighTide Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.71B | -1.9x | -0.04 | HK$3.21 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tot Biopharm Intl | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.45B | 37x | 0.2 | HK$1.88 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.7% Upside | Upgrade to Pro+ | |
Brii Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.30B | -2.6x | 0.01 | HK$1.81 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -43.6% Downside | Upgrade to Pro+ | |
Genor Biopharma Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.21B | -19.9x | -0.22 | HK$2.53 | 8.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Wuhan YZY Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$816.11M | -8.3x | -0.16 | HK$4.21 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sunho Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$813.60M | -6.7x | -0.16 | HK$5.12 | -5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jw Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$668.85M | -1x | -0.04 | HK$1.67 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.5% Upside | Upgrade to Pro+ | |
Kintor Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$538.41M | -3.3x | -0.04 | HK$1.22 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$310.94M | -0.6x | -0.02 | HK$3.05 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Clover Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$250.33M | -0.3x | 0 | HK$0.20 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Health Inc | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$159.26M | -14.8x | -0.13 | HK$0.16 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laekna | Hong Kong | Healthcare | Biotechnology & Medical Research | -0.35 | HK$14.16 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.9% Upside | Upgrade to Pro+ |